+Vote!
Market Wire (Free subscription) | 6 hours ago
DENVER, CO (MARKET WIRE) Dyer & Berens LLP (www.DyerBerens.com) today announced that it has filed a class action lawsuit in the United States District Court for the Eastern District of Pennsylvania, Civil Action No. 09-cv-5262, on behalf of all purchasers of the securities of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (AMEX: HEB) between February 18, 2009...
3Vote!
GuruFocus Updates (Free subscription) | yesterday
By 10qk. Hemispherx Biopharma Inc ( HEB ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
4Vote!
Market Wire (Free subscription) | 11/04/2009
... DRH), Lloyds Banking Group plc (NYSE: LYG), Canadian National Railway Company (NYSE: CNI) and Hemispherx Biopharma Inc. (AMEX: HEB).
4Vote!
Stock Market Analysis (Free subscription) | 11/03/2009
... positive Bakken Shale well. Pre Market Stock Losers - 11/3/09 GSI Group Inc. (GSIG) - No News Hemispherx Biopharma, Inc. (HEB) - Hemispherx Biopharma Updates Chronic Fatigue Syndrome (CFS) Drug Ampligen Allied Irish Banks plc (AIB) - RBS news has Irish Bank sector lower The Bank of Ireland (IRE) - RBS news Royal Bank (RBS) - RBS, LLoyd's to sell more assets Hot Stocks to Watch List...
5Vote!
The Street (Free subscription) | 11/03/2009
PHILADELPHIA, Pa. () --Hemispherx Biopharma() issued an "update" to the regulatory status of its chronic fatigue syndrome drug Ampligen in which the company essentially admits that its prior public statements were false and misleading. More from Adam Feuerstein Market Activity | | Monday's statement was likely crafted by Hemispherx's lawyers as a way to help CEO Bill Carter wiggle out of public...
